CAR-T cell therapy has shown some really promising results for myeloma, especially for people whose cancer has relapsed or been hard to treat. Here's a quick summary of what research has found:
- About 3 in 4 people saw reduced signs of cancer
- 1 in 3 people had a complete response, meaning all signs of cancer were gone
- Show Full Answer
CAR-T cell therapy has shown some really promising results for myeloma, especially for people whose cancer has relapsed or been hard to treat. Here's a quick summary of what research has found:
- About 3 in 4 people saw reduced signs of cancer
- 1 in 3 people had a complete response, meaning all signs of cancer were gone
- A recent study found that 1 in 3 people remained in remission for at least 5 years after just a single infusion — with no ongoing treatment needed That said, CAR-T doesn't work for everyone, and there are some important risks to be aware of, including:
- Cytokine Release Syndrome (CRS) — flu-like symptoms that can occasionally be serious
- Neurotoxicity — confusion or trouble speaking
- Other side effects like fatigue, infections, nausea, and fever Since you're currently two months into maintenance therapy, it's worth knowing that research suggests staying on maintenance longer can improve outcomes — some doctors recommend continuing indefinitely as long as side effects are manageable.
CAR-T is typically considered for relapsed or hard-to-treat cases, so it's a great conversation to have with your doctor about where it might fit into your overall treatment journey.
September 1
Join
Your Privacy Choices
